Pfizer (PFE) has continued its relatively orderly ascent. I am recommending we roll our put out two weeks to generate more income and reduce our net debit on the position. You can enter the second leg of today’s trade even if you were not in the previous one. Just be aware that we will be…
Pfizer (PFE) has continued its relatively orderly ascent. I am recommending we roll our put out two weeks to generate more income and reduce our net debit on the position. You can enter the second leg of today’s trade even if you were not in the previous one. Just be aware that we will be…
Pfizer (PFE) continued its ascent this week. I am recommending we roll our put out two weeks and to a higher strike price to generate more income and reduce our net debit on the position. You can enter the second leg of today’s trade even if you were not in the previous one. Just be…
Pfizer (PFE) continued its ascent this week. I am recommending we roll our put out two weeks and to a higher strike price to generate more income and reduce our net debit on the position. You can enter the second leg of today’s trade even if you were not in the previous one. Just be…
I am recommending we roll our Pfizer (PFE) put out one week and to a higher strike price to generate more income and reduce our net debit on the position. You can enter the second leg of today’s trade even if you were not in the previous one. Just be aware that we will be…
I am recommending we roll our Pfizer (PFE) put out one week and to a higher strike price to generate more income and reduce our net debit on the position. You can enter the second leg of today’s trade even if you were not in the previous one. Just be aware that we will be…
Pfizer (PFE) announced a clean beat on the top and bottom lines this week and raised its full-year earnings forecast and the lower end of its revenue guidance. It also increased its full-year sales guidance for its COVID-19 vaccine by $2 billion to $34 billion. Additionally, the company says it has enough promising data on…
Pfizer (PFE) announced a clean beat on the top and bottom lines this week and raised its full-year earnings forecast and the lower end of its revenue guidance. It also increased its full-year sales guidance for its COVID-19 vaccine by $2 billion to $34 billion. Additionally, the company says it has enough promising data on…
Pfizer (PFE) has run up more than 10% since we last rolled our call, moving too fast and too far to make rolling our PFE Oct Week Four (10/28) 43.50 Call up to capture more appreciation feasible. Additionally, the company is expected to report earnings on Nov. 1. Therefore, we are going to allow our…
Pfizer (PFE) has run up more than 10% since we last rolled and our PFE Oct Week Four (10/28) 43.50 Call is deep in the money. With the company is expected to report earnings on Nov. 1, we are going to allow our shares to be called away. My hope is that we can get…
